The Technical Analyst
Autolus Therapeutics PLC [AUTL]
Exchange: NasdaqGS Sector: Healthcare Industry: Biotechnology
Autolus Therapeutics PLC Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: SELL (auto-tracking)
-2.83% $2.75
Last updated: 3 jul 2022 - 19:37
TimeZone: America/New_York
FIND ALL MARKETS
FIND ALL STOCKS LISTED @ NASDAQ Live Signal Oslo
Live Signal Nasdaq
Live Signal Crypto
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 250.03 mill |
| EPS: | -1.842 |
| P/E: | 0.000 |
| Earnings Date: | May 04, 2022 |
| SharesOutstanding: | 90.92 mill |
| Avg Daily Volume: | 0.215 mill |
| RATING 2022-07-01 |
|---|
| B+ |
| Neutral |
| RATINGDETAILS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Sell | |
| Return On Asset: | Sell | |
| DE: | Neutral | |
| P/E: | Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 4/20 | 1/21 | 2/21 | 3/21 | 4/21 | 1/22 | |
| Revenue | n/a | n/a | ||||
| Gr.Profit | n/a | n/a | n/a | n/a | n/a | |
| Ebit | ||||||
| Asset | ||||||
| Debt |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$7.06 (156.55%) $4.31 |
| Date: 2022-07-03 |
| True Range Average |
|---|
|
+/- $0.223 ( +/- 8.11%) Range: 2.53 - 2.97 |
| ATR Model: 14 days |
Forecast:
16:00 - $2.76
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $2.76
Forecast 2: 16:00 - $2.76
Forecast 3: 16:00 - $2.76
SCORE
-10.00
Sell
-10.00
Sell
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $2.75 (-2.83% ) |
| Volume | 0.0636 mill |
| Avg. Vol. | 0.215 mill |
| % of Avg. Vol | 29.54 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For AUTL
26 Signals | Accuracy: 15.38% | Accuracy Buy: 23.08% | Accuracy Sell: 7.69%
Avg return buy: -0.40 % | Avg return sell: 0.19 %
$1 invested is now $0.95 or -5.10% since 30-06-22
| Date | Signal | @ | Closed | % | Jul 1 - 15:45 | sell | $2.75 | N/A | Active |
|---|---|---|---|---|
| Jul 1 - 15:38 | buy | $2.78 | $2.75 @ Jul 1 - 15:45 | -1.08% |
| Jul 1 - 15:15 | sell | $2.78 | $2.78 @ Jul 1 - 15:38 | 0.00% |
| Jul 1 - 15:06 | buy | $2.79 | $2.78 @ Jul 1 - 15:15 | -0.36% |
| Jul 1 - 11:40 | sell | $2.89 | $2.79 @ Jul 1 - 15:06 | -3.29% |
| Jul 1 - 11:26 | buy | $2.89 | $2.89 @ Jul 1 - 11:40 | 0.00% |
| Jul 1 - 11:03 | sell | $2.88 | $2.89 @ Jul 1 - 11:26 | 0.17% |
| Jul 1 - 10:55 | buy | $2.90 | $2.88 @ Jul 1 - 11:03 | -0.52% |
| Jul 1 - 10:43 | sell | $2.88 | $2.90 @ Jul 1 - 10:55 | 0.52% |
| Jul 1 - 10:12 | buy | $2.86 | $2.88 @ Jul 1 - 10:43 | 0.62% |
AUTL
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of hematological malignancies and solid tumors. The company is developing AUTO1 and AUTO3 for B cell malignancies; AUTO2 for the treatment of multiple myeloma; AUTO4 and AUTO 5 for T cell lymphoma; and AUTO6 and AUTO7 to treat solid tumors. The company was founded in 2014 and is headquartered in London, the United Kingdom.
Latest Press Releases
2022-06-10 03:01:00 - Press Release
Autolus Therapeutics Presents Clinical Data Updates At The European Hematology Association Congress
- auto4 shows high level of clinical activity with a novel targeting approach for patients with t cell lymphoma - auto1/22 demonstrates encouraging and durable responses in children ineligible for commercial car t product - obe-cel shows high level of sustained clinical activity in b-nhl patients and first activity in primary cns lymphoma
2022-05-31 16:01:00 - Press Release
Autolus To Hold Annual General Meeting (agm) Of Shareholders On Tuesday, June 28, 2022
London, may 31, 2022 (globe newswire) -- autolus therapeutics plc (nasdaq: autl), a clinical-stage biopharmaceutical company developing next-generation programmed t cell therapies, today posted notice of its annual general meeting (agm) to shareholders (the "notice"), which can be viewed and downloaded from www.autolus.com. the agm is scheduled to be held at the studio, westworks, white city place, london w12 7fq on tuesday, june 28, 2022, commencing at 8:00 a.m. bst.
2022-05-27 07:45:00 - Press Release
Autolus Therapeutics To Participate In The Jefferies Healthcare Conference, Being Held In New York From June 8 – 10, 2022
London, may 27, 2022 (globe newswire) -- autolus therapeutics plc (nasdaq: autl), a clinical-stage biopharmaceutical company developing next-generation programmed t cell therapies, today announces that management will be attending the jefferies healthcare conference at the marriott marquis in new york city. autolus' chief executive officer dr. christian itin will participate in a fireside chat on thursday, june 9 at 9.00 – 9.30 am et (2:00 pm – 2.30 pm bst) and the company will also be attending one-on-one investor meetings at the event.
2022-05-05 07:00:00 - Press Release
Autolus Therapeutics Reports First Quarter 2022 Financial Results And Operational Progress
- conference call to be held on may 5, 2022 at 8:30 am et/1:30 pm bst - - conference call to be held on may 5, 2022 at 8:30 am et/1:30 pm bst -
2022-04-25 07:01:00 - Press Release
Fda Grants Regenerative Medicine Advanced Therapy (rmat) Designation To Autolus' Car T Cell Therapy, Obe-cel, For The Treatment Of adult B-all
London, april 25, 2022 (globe newswire) -- autolus therapeutics plc (nasdaq: autl), a clinical-stage biopharmaceutical company developing next-generation programmed t cell therapies, today announced that the u.s. food and drug administration (fda) has granted regenerative medicine advanced therapy (rmat) designation to its lead gene therapy obecabatagene autoleucel (obe-cel), a cd19-directed autologous chimeric antigen receptor (car) t therapy that is being investigated in the ongoing felix phase 2 study of adult relapsed / refractory b-acute lymphocytic leukemia (all).
Latest News
2022-05-17 15:07:08 - GuruFocus
Caribou Charges Ahead on Study Results
Shares of Caribou Biosciences Inc. ( CRBU , Financial) are up more than 46% since last Thursday, leading the way for several beaten-down biotechs that also rose after investors got a look at the presentations the companies will be making at next month's European Hematology Association meeting.
2022-05-12 10:51:00 - GlobeNewsWire
Autolus Therapeutics to Present Four Clinical Data Updates at the European Hematology Association Congress
- AUTO4: oral presentation on initial clinical experience in peripheral T cell lymphoma - AUTO1/22: oral presentation on initial experience in r/r pediatric B-cell acute lymphoblastic leukemia - obe-cel: poster presentation in r/r primary CNS lymphoma - obe-cel: poster presentation in r/r B-non-Hodgkins lymphoma and chronic lymphoblastic leukemia - Conference call to be held on June 13, 2022 at 7:30 am EST/12:30 pm BST
2022-05-08 03:59:04 - Seeking Alpha
Autolus Therapeutics plc (AUTL) CEO Christian Itin on Q1 2022 Results - Earnings Call Transcript
Autolus Therapeutics plc (NASDAQ:AUTL ) Q1 2022 Earnings Conference Call May 5, 2022 8:30 AM ET Company Participants Olivia Manser - Director, Investor Relations Christian Itin - Chief Executive Officer Lucinda Crabtree - Chief Financial Officer Conference Call Participants Matt Phipps - William Blair Nick Abbott - Wells Fargo Mara Goldstein - Mizuho Gil Blum - Needham Simon Baker - Redburn Operator Ladies and gentlemen, thank you for standing by and welcome to the Autolus Therapeutics First Quarter 2022 Financial Results Conference Call. [Operator Instructions] I would now like to hand the conference over to your speaker today, Olivia Manser, Director of Investor Relations.
2022-04-25 07:00:00 - GlobeNewsWire
Autolus Therapeutics to Report First Quarter 2022 Financial Results and Host Conference Call on May 5
LONDON, April 25, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will release its first quarter 2022 financial results and operational highlights before open of U.S. markets on Thursday, May 5, 2022.
2022-03-10 13:58:03 - Seeking Alpha
Autolus Therapeutics plc (AUTL) CEO Dr. Christian Itin on Q4 2021 Results - Earnings Call Transcript
Autolus Therapeutics plc (AUTL) CEO Dr. Christian Itin on Q4 2021 Results - Earnings Call Transcript
2022-02-21 07:00:00 - GlobeNewsWire
Autolus Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call on March 10
LONDON, Feb. 21, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will release its fourth quarter and full year 2021 financial results and operational highlights before open of U.S. markets on Thursday, March 10, 2022.
2022-01-19 12:19:17 - Zacks Investment Research
Autolus Therapeutics PLC Sponsored ADR (AUTL) Loses 22.1% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
The heavy selling pressure might have exhausted for Autolus Therapeutics PLC Sponsored ADR (AUTL) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
2022-01-05 07:00:00 - GlobeNewsWire
Autolus Therapeutics to Present at Conferences During January 2022
LONDON, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that they are scheduled to deliver a corporate presentation at the following virtual conferences:
2021-11-09 08:30:43 - Invezz
Market Highlights: Stocks react to earnings release, Blackstone invests $250 billion in Autolus, Elon Musk to sell 10% Tesla stake
Roblox Corp (NYSE: RBLX) shares jumped 30% after hours on Monday after the company posted robust fiscal Q3 results thanks to demand surge with the easing of COVID-19 restrictions. As a result, the video game company reported a loss of $74 million or $0.13 per share compared to a net loss of $48.6 million or […] The post Market Highlights: Stocks react to earnings release, Blackstone invests $250 billion in Autolus, Elon Musk to sell 10% Tesla stake appeared first on Invezz.
2021-11-08 21:29:22 - The Motley Fool
Why Autolus Therapeutics Stock Jumped 25% Today
